By Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated results from the DESTINY-Breast03 phase III clinical trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.
T-DXd leads to longer overall survival in HER2-positive metastatic breast cancer patients than T-DM1
Close up of chemical microscope and medical research equipment in scientific laboratory. Liquid examination tool with glass lens and blood samples in vacutainers on professional desk
Comments